HC Wainwright Reaffirms Neutral Rating for Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “neutral” rating reiterated by investment analysts at HC Wainwright in a report issued on Thursday,Benzinga reports. They currently have a $40.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target would suggest a potential upside of 5.54% from the stock’s previous close.

A number of other analysts have also weighed in on the company. JPMorgan Chase & Co. cut their price objective on Sarepta Therapeutics from $169.00 to $84.00 and set an “overweight” rating on the stock in a research report on Tuesday. Guggenheim cut their price target on Sarepta Therapeutics from $112.00 to $98.00 and set a “buy” rating on the stock in a report on Wednesday, May 7th. Piper Sandler decreased their price objective on Sarepta Therapeutics from $110.00 to $70.00 and set an “overweight” rating for the company in a research note on Wednesday, May 7th. Needham & Company LLC lowered their price objective on Sarepta Therapeutics from $183.00 to $125.00 and set a “buy” rating for the company in a research report on Wednesday, May 7th. Finally, Deutsche Bank Aktiengesellschaft reduced their target price on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating on the stock in a report on Wednesday, March 19th. Six research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $122.61.

Sarepta Therapeutics Stock Performance

Shares of Sarepta Therapeutics stock opened at $37.90 on Thursday. The stock has a market capitalization of $3.72 billion, a price-to-earnings ratio of 30.32 and a beta of 0.85. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The business has a 50-day moving average of $54.60 and a 200 day moving average of $94.62. Sarepta Therapeutics has a 12 month low of $34.10 and a 12 month high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing the consensus estimate of $2.20 by ($5.62). The business had revenue of $744.86 million for the quarter, compared to analyst estimates of $685.75 million. Sarepta Therapeutics had a return on equity of 11.00% and a net margin of 7.43%. The firm’s revenue for the quarter was up 80.2% compared to the same quarter last year. During the same period in the prior year, the company posted $0.73 EPS. As a group, sell-side analysts forecast that Sarepta Therapeutics will post 2.67 earnings per share for the current year.

Insider Activity

In other news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the sale, the director now directly owns 27,812 shares of the company’s stock, valued at approximately $2,771,187.68. This represents a 8.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 7.70% of the company’s stock.

Hedge Funds Weigh In On Sarepta Therapeutics

A number of institutional investors have recently modified their holdings of SRPT. Charles Schwab Investment Management Inc. boosted its stake in Sarepta Therapeutics by 2.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 623,749 shares of the biotechnology company’s stock worth $75,842,000 after purchasing an additional 12,000 shares during the period. Proficio Capital Partners LLC purchased a new stake in shares of Sarepta Therapeutics in the fourth quarter valued at about $3,829,000. Allspring Global Investments Holdings LLC boosted its stake in shares of Sarepta Therapeutics by 16,717.7% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 85,434 shares of the biotechnology company’s stock worth $10,602,000 after buying an additional 84,926 shares during the period. Van ECK Associates Corp grew its holdings in shares of Sarepta Therapeutics by 24.4% during the fourth quarter. Van ECK Associates Corp now owns 84,834 shares of the biotechnology company’s stock worth $10,315,000 after buying an additional 16,658 shares during the last quarter. Finally, Sivik Global Healthcare LLC purchased a new position in shares of Sarepta Therapeutics during the fourth quarter worth about $1,216,000. 86.68% of the stock is owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.